Contact the Team

The Alnylam Assist Team is comprised of individuals with diverse backgrounds and expertise in healthcare support and delivery.

8 AM - 7PM ET,

Monday-Friday

Phone:1-833-256-2748

How We Can Help

Case
Managers

  • Benefit verification and explanation
  • Financial assistance for eligible patients*
  • Facilitation of product orders

Field Reimbursement Directors

  • ONPATTRO billing and coding requirements
  • Chart documentation requirements
  • Payer requirements

Patient Education
Liaisons

  • Disease and product education
  • Setting treatment expectations
  • Additional resources for patients and their families

Personalized Support Throughout the Treatment Process

Graphic

Separator

Discover More

Patient Services

Learn more about how Alnylam Assist supports
patients being treated with ONPATTROTM.

Get the Facts

Forms and Documents

For more information about Alnylam Assist
and treatment with ONPATTRO.

See Materials

Take Action Now1

Take Action Now

Together with your patient (in office)

Initiate then send to patient (over email)

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTROTM (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

Indication

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.